Cannabinoid CB1 receptors have been a potential target for nonopioid-based pain treatment, but actually targeting the pathway has been hindered by issues with tolerance and unwanted CNS side effects.

Led by researchers at the University of Laval in Canada, the study found that mice with increased levels of cannabinoid receptor 1 (CB1) on certain brain cells show significantly fewer behaviors ...

CBD and THC, both derived from cannabis, interact differently with our bodies, leading to varied effects and potential ...

Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development ...

Two videoconferences will be held tomorrow, March 27, 2025in French at 05:30pm CET and in English at 07:30pm CET (02:30pm ET) ...

THC binds to the CB1 receptor, found in the brain, but also in the myocardium, vascular endothelial, and smooth muscle cells. The CB1 receptor promotes atherosclerotic changes, Chandy explained ...

They bind to a receptor, called cannabinoid receptor one (CB1), on the surface of brain cells and on pain-sensing nerve cells throughout the body. Working with collaborators at Stanford University ...

Read the paper: A cryptic pocket in CB1 drives peripheral and functional selectivity Many important drug targets are G-protein-coupled receptors (GPCRs), including those activated by blockbuster ...